This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parker, C. R. Articles by Hosking, D. J. Search for Related Content PubMed PubMed Citation Articles by Parker, C. R. Articles by Hosking, D. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL PARATHYROID HORMONE Medline Plus Health Information Osteoporosis

Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study

Division of Mineral Metabolism (C.R.P., D.J.H.) and Departments of Clinical Chemistry (P.J.B.) and Radiology (K.J.F.), City Hospital, Nottingham NG5 1PB, United Kingdom

Address all correspondence and requests for reprints to: Cornelle R. Parker, M.D., Airedale General Hospital, Skipton Road, Steeton, Keighley, West Yorkshire BD20 6TD, United Kingdom. E-mail: cparker{at}doctors.org.uk.

Abstract

We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism. The treatment group [n = 14; T score -2.5 SD at the femoral neck (FN) or T -1.0 SD plus previous nonvertebral fracture] was given alendronate 10 mg/d for 24 months. The second group (n = 18; T score > -2.5 SD at the FN) was untreated. Biochemistry was repeated at 1.5, 3, 6, 12, 18, and 24 months, and dual-energy x-ray absorptiometry at 12 and 24 months.

There were no significant between-group baseline differences in calcium, creatinine, or PTH. Alendronate-treated patients gained bone at all sites [lumbar spine (LS), 1 yr gain, +7.3 ± 1.7%; P < 0.001; 2 yr, +7.3 ± 3.1%; P = 0.04). Untreated patients gained bone at the LS over 2 yr (+4.0 ± 1.8%; P = 0.03) but lost bone elsewhere. Calcium fell nonsignificantly in the alendronate group between baseline (2.84 ± 0.12 mmol/liter) and 6 wk (2.76 ± 0.09 mmol/liter), with a nonsignificant rise in PTH (baseline, 103.5 ± 14.6 ng/liter; 6 wk, 116.7 ± 15.6 ng/liter). By 3 months, values had reverted to baseline.

In primary hyperparathyroidism, alendronate is well tolerated and significantly improves bone mineral density at the LS (with lesser gains at FN and radius), especially within the first year of treatment. Short-term changes in calcium and PTH resolve by 3 months.

This article has been cited by other articles:

				N. Farag, T. Delbanco, and G. J. Strewler Update: A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, November 5, 2008; 300(17): 2044 - 2045. [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				A. A. Khan, J. P. Bilezikian, A. W. C. Kung, M. M. Ahmed, S. J. Dubois, A. Y. Y. Ho, D. Schussheim, M. R. Rubin, A. M. Shaikh, S. J. Silverberg, et al. Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3319 - 3325. [Abstract] [Full Text] [PDF]

				J. P. Bilezikian and S. J. Silverberg Asymptomatic Primary Hyperparathyroidism N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751. [Full Text] [PDF]